Clinuvel Pharmaceuticals Limited (FRA:UR9A)

Germany flag Germany · Delayed Price · Currency is EUR
6.60
+0.05 (0.76%)
At close: Dec 4, 2025
-14.84%
Market Cap 352.86M
Revenue (ttm) 53.04M
Net Income (ttm) 20.19M
Shares Out n/a
EPS (ttm) 0.40
PE Ratio 17.47
Forward PE 16.64
Dividend 0.02 (0.35%)
Ex-Dividend Date Sep 8, 2025
Volume n/a
Average Volume n/a
Open 6.60
Previous Close 6.55
Day's Range 6.60 - 6.60
52-Week Range 5.00 - 7.75
Beta n/a
RSI 66.43
Earnings Date Nov 27, 2025

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 16
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol UR9A
Full Company Profile

Financial Performance

In 2025, Clinuvel Pharmaceuticals's revenue was 95.02 million, an increase of 7.76% compared to the previous year's 88.18 million. Earnings were 36.17 million, an increase of 1.50%.

Financial numbers in AUD Financial Statements

News

There is no news available yet.